Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Is Jumping Today

By George Budwell – May 19, 2020 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dynavax's COVID-19 vaccine program is turning heads this morning.

What happened

Shares of the small-cap biotech Dynavax Technologies Corporation (DVAX 3.54%) are poised for a big day today. In pre-market action, the company's shares rose by as much as 43% on heavy volume. Investors are bidding up Dynavax's shares this morning in anticipation of the company's COVID-19 vaccine program update, which is scheduled for later today.

One of the main reasons for all the excitement is that Dynavax has already announced that one or more of its collaboration partners should initiate an early stage COVID-19 vaccine trial by July. Today's meeting will likely provide additional information on the state of these partnerships. 

A doctor holding a bottle containing a COVID-19 vaccine.

Image source: Getty Images.

So what

Dynavax's current plan is to provide its proprietary toll-like receptor 9 agonist adjuvant CpG-1018 -- the same adjuvant used in the company's FDA-approved hepatitis B vaccine, Heplisav B -- to its partners in order to boost the effectiveness of these experimental COVID-19 vaccines. Dynavax should thus be in line to receive a portion of any future grant funding. That's definitely a positive, as several companies have now received sizable grants to develop a vaccine against the deadly respiratory virus. On the flip side, there's also no guarantee that more funding will indeed materialize.  

Now what

Dynavax's shares have been grossly undervalued for a while now. Heplisav-B, after all, should eventually generate several hundred million dollars in peak sales. So if you're buying this biotech stock for its tie-in to the ongoing pandemic, it might be a good idea to stay for the company's real value driver: Heplisav-B's rapidly growing sales.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
$10.81 (3.54%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.